Search

everythinglearnresearchcommunity

for

Search:↓

The research found that polycystic ovary syndrome (PCOS) has two distinct types, with one having more severe hormone and insulin issues.

Excessive hair growth can be assessed by history, exam, and blood tests, and treated with medication like dexamethasone, birth control pills, and spironolactone.

PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.

Young girls whose mothers have PCOS may have higher activity of a specific enzyme that could lead to developing PCOS later.

Neurosteroids change how GABA_A receptors work in the brain, which could be important for treating temporal lobe epilepsy.

The mineralocorticoid receptor may play a role in skin and hair health and could be a new target for treating related disorders.

Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.

About 8.5% of women in Salvador, Brazil, have Polycystic Ovary Syndrome.

Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.

Weight loss and metformin don't significantly change vaspin levels in women with PCOS.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Women with only irregular periods or excess hair have a better hormone profile than those with full PCOS, but both groups are similar, indicating a need for better PCOS diagnosis methods.

Adult skin quickly reacts to short-term environmental and internal stress, leading to various skin issues and the need for protective measures.

Hirsutism is excessive male-pattern hair growth in women, often caused by hormonal imbalances, and requires ongoing treatment to manage.

Hair problems are common and distressing for women, but increasing knowledge of treatments offers hope.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

Minoxidil effectively treats female pattern hair loss.

Metformin improves menstrual cycles and hormone levels in women with PCOS, mostly within the first 6 months.

High afamin levels are linked to metabolic syndrome and may predict its development in women with insulin resistance.

Finasteride reduces hair growth and is safe for women with excessive hair.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

Dutasteride makes alcohol less sedating and may lead to less drinking in men.

Brazilian women with PCOS and both menstrual irregularity and high male hormone levels have a higher chance of having metabolic syndrome.

Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.

Hormonal treatments are effective as a second-line option for moderate-to-severe acne in females, but should be used with caution due to health risks.

Neuroactive steroids could become safe, effective treatments with more understanding of their complex brain actions and metabolism.

A natural steroid in the body may protect against eye damage in glaucoma.

Testosterone therapy may slightly improve sexual function in postmenopausal women, but its long-term safety is unknown.

Young women with PCOS have a higher risk of high blood pressure and metabolic syndrome, but these risks may decrease after age 40.

Continuous light exposure in rats leads to PCOS-like symptoms and suggests sleep habits might affect the disorder's development.